<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730258</url>
  </required_header>
  <id_info>
    <org_study_id>TWT-202</org_study_id>
    <nct_id>NCT04730258</nct_id>
  </id_info>
  <brief_title>A Study of CFI-400945 With or Without Azacitidine or Decitabine in Patients With AML, MDS or CMML</brief_title>
  <acronym>TWT-202</acronym>
  <official_title>Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine or Decitabine in Patients With AML, MDS or CMML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Treadwell Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Treadwell Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of an investigational drug called CFI-400945&#xD;
      alone and in combination with azacitidine or decitabine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be evaluating the safety and tolerability of CFI-400945 in subjects with&#xD;
      Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia. The&#xD;
      study is designed to build on encouraging data from another study and to obtain further&#xD;
      safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) data of CFI-400945.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation and expansion for monotherapy and combination arms with azacitidine or decitabine</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent AEs</measure>
    <time_frame>36 months</time_frame>
    <description>The number of subjects who experience an adverse event that was possibly related to study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment emergent changes in vital signs</measure>
    <time_frame>36 months</time_frame>
    <description>The number of subjects who experience changes in blood pressure, heart rate, respiratory rate, body temperature that was possibly related to study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment emergent changes in clinical laboratory tests</measure>
    <time_frame>36 months</time_frame>
    <description>The number of subjects who experience a change in laboratory parameters that was possibly related to study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment emergent changes in physical examinations, ECOG performance status, electrocardiograms (ECGs), echocardiograms and cardiac troponins</measure>
    <time_frame>36 months</time_frame>
    <description>The number of subjects who experience changes in physical examinations, performance status, ECG, troponins that were possibly related to study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Complete Remission Rate, CRc (complete remission + complete remission with incomplete blood count recovery + complete remission with incomplete platelet count recovery [CR + CRi + CRp])</measure>
    <time_frame>36 months</time_frame>
    <description>Response rate will be summarized by dose cohort and overall using the percent of patients in patient with AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR, defined as Complete remission + Marrow CR + Partial remission + Hematologic Improvement (CR + mCR+ PR + HI)</measure>
    <time_frame>36 months</time_frame>
    <description>Response rate will be summarized by dose cohort and overall using the percent of patients in patients with MDS, CMML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetics of CFI-400945 will be assessed through AUC.</measure>
    <time_frame>36 months</time_frame>
    <description>Area under the plasma concentration (AUC) versus time curve from time 0 to time of least measurable concentration tabulated by dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetic profile of CFI-400945 through Cmax.</measure>
    <time_frame>36 months</time_frame>
    <description>Cmax will be assessed through the maximum measured plasma concentration occurring at Tmax tabulated by dose group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetic profile of CFI-400945 through T1/2.</measure>
    <time_frame>36 months</time_frame>
    <description>Elimination half life will be calculated and tabulated by dose group.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>AML</condition>
  <condition>MDS</condition>
  <condition>CMML</condition>
  <arm_group>
    <arm_group_label>1A: Monotherapy escalation and expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation and expansion arm with CFI-400945</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1B: Food Effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Food effect at the recommended phase 2 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2A: Combination escalation and expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation and expansion arm with CFI-400945 and azacitidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2B: Combination escalation and expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation and expansion arm with CFI-400945 and decitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFI-400945</intervention_name>
    <description>The starting dose is 32 mg/day for escalation arms and the recommended starting dose for the expansion arms.</description>
    <arm_group_label>1A: Monotherapy escalation and expansion</arm_group_label>
    <arm_group_label>1B: Food Effect</arm_group_label>
    <arm_group_label>2A: Combination escalation and expansion</arm_group_label>
    <arm_group_label>2B: Combination escalation and expansion</arm_group_label>
    <other_name>CFI-400945 fumarate</other_name>
    <other_name>945</other_name>
    <other_name>400945</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine will be given at its labeled dose and schedule</description>
    <arm_group_label>2A: Combination escalation and expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Decitabine will be given at its labeled dose and schedule</description>
    <arm_group_label>2B: Combination escalation and expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be &gt;18 years of age&#xD;
&#xD;
          2. For Parts 1A and 1B, the following malignancy types will be included:&#xD;
&#xD;
               1. Relapsed or refractory AML.&#xD;
&#xD;
               2. MDS, after prior hypomethylating agents.&#xD;
&#xD;
               3. CMML, with progressive disease/lack of response after hypomethylating agents&#xD;
&#xD;
             For Parts 1A and 1B, Patients may have relapsed or refractory disease.&#xD;
&#xD;
          3. For Parts 2A and 2B, the following malignancy types will be included:&#xD;
&#xD;
               1. Relapsed or Refractory AML.&#xD;
&#xD;
               2. MDS patients should be limited to high risk disease&#xD;
&#xD;
               3. MDS or CMML should be previously untreated and patients with AML may have&#xD;
                  relapsed or refractory disease;&#xD;
&#xD;
          4. Have clinically acceptable laboratory screening results (i.e., clinical chemistry,&#xD;
             hematology, and urinalysis) within certain limits per protocol.&#xD;
&#xD;
          5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have received investigational therapy, radiotherapy, immunotherapy,&#xD;
             monoclonal antibodies, or chemotherapy within 14 days or 5 half-lives (whichever is&#xD;
             shorter)&#xD;
&#xD;
          2. Allogeneic or autologous transplant for AML with infusion of stem cells within 90 days&#xD;
             before Cycle 1 Day 1, or on active immunosuppressive therapy for graft-versus-host&#xD;
             disease (GVHD) or GVHD prophylaxis within 2 weeks of Cycle 1 Day 1.&#xD;
&#xD;
          3. Any Grade ≥ 2 persistent non-hematological toxicity related to allogeneic transplant,&#xD;
             such as those requiring systemic immunosuppressive therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gautam Borthakur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas MD Anderson Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Treadwell Therapeutics Clinical Trials</last_name>
    <phone>+1-416-455-7510</phone>
    <email>clinicaltrials@treadwelltx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Jonas, MD</last_name>
      <email>brian.jonas@ucdmc.ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Linh Dang-Chu</last_name>
      <email>ldangchu@ucdavis.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute - Saint Matthews</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Centre</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gautam Borthakur</last_name>
      <email>gborthak@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polo-like kinase 4</keyword>
  <keyword>PLK4</keyword>
  <keyword>serine/threonine kinase Polo-like kinase 4</keyword>
  <keyword>CFI-400945</keyword>
  <keyword>945</keyword>
  <keyword>Polo-Like Kinase 4 inhibitors/antagonists</keyword>
  <keyword>hematologic malignancies</keyword>
  <keyword>PLK-4</keyword>
  <keyword>UHN</keyword>
  <keyword>University Health Network</keyword>
  <keyword>Treadwell</keyword>
  <keyword>Treadwell Therapeutics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>It is too early to determine whether we will make IPD available - we do not yet have a process written on this. Field will be updated once our policy / process is written.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

